Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

IntroductionBelimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ open 2019-03, Vol.9 (3), p.e025687-e025687
Hauptverfasser:	Teng, Y K Onno, Bruce, Ian N, Diamond, Betty, Furie, Richard A, van Vollenhoven, Ronald F, Gordon, David, Groark, James, Henderson, Robert B, Oldham, Mary, Tak, Paul P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Arthritis Clinical trials Clinical Trials, Phase III as Topic Disease control Double-Blind Method Double-blind studies Female Humans Immunology Immunosuppressive agents Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunotherapy Injections, Subcutaneous Lupus Lupus Erythematosus, Systemic - drug therapy Male Middle Aged Monoclonal antibodies Multicenter Studies as Topic Prednisone - administration & dosage Quality of life Randomized Controlled Trials as Topic Rheumatology Rituximab - administration & dosage Rituximab - adverse effects Severity of Illness Index Treatment Outcome Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!